• Explore /
  • Poster
  • / Pharmacodynamics and gene expression analysis of patients with renal cell carcinoma treated with combination nivolumab and TPST-1120 in a phase I clinical trial (NCT03829436).

Pharmacodynamics and gene expression analysis of patients with renal cell carcinoma treated with combination nivolumab and TPST-1120 in a phase I clinical trial (NCT03829436).

Abstract Poster

Authors

Bruno Bastos

Bruno R. Bastos

Miami Cancer Institute, Baptist Health South Florida, Miami, FL

Bruno R. Bastos , Nathan Standifer , Rohan Garje , Sam H. Whiting

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03829436

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 438)

DOI

10.1200/JCO.2024.42.4_suppl.438

Abstract #

438

Poster Bd #

H20

Abstract Disclosures

Similar Posters

First Author: Susanna Varkey Ulahannan

Poster

2023 ASCO Genitourinary Cancers Symposium

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

First Author: Jianbo Wang

First Author: Luis Teixeira

First Author: Ginna Laport